

26 The sensitivity becomes considerably low when the samples are pooled, there is a higher
27 percentage of false negatives with higher pool size and when the patient viral load is low or
28 weak positive samples. High variability was seen in the intra and inter assay, especially in weak
29 positive samples and larger pool size.

30 Conclusion

31 As COVID - 19 numbers are still high and testing capacity needs to be high, we have to
32 meticulously evaluate the testing strategy for each country depending on its testing capacity,
33 infrastructure, economic strength, and need to make a serious call on cost effective strategy of
34 resource saving and risk/ cost of missing positive patients.

35 **Key words:** COVID-19; SARS-CoV-2; diagnosis; mass screening; sample pooling;

36 Background

37 The world in 2020 has been witnessing the most crippling pandemic on earth, ever since its
38 outbreak in December 2019 at Wuhan, China. It is widely known as COVID-19, caused by
39 SARS- COV- 2 virus, it's a new virus and not much has been known about the virus. From
40 what is known the virus seems to exhibit a variable incubation period which can be up to 14
41 days and asymptomatic carriers can also transmit the virus, it spreads rapidly and affected large
42 number of people than SARS and MERS, despite having lower case fatality rate. ¹ All these
43 characteristics of the novel virus has made the containment and control of the virus challenging.

44 The World Health Organization (WHO) has recommended robust diagnostic testing to
45 differentiate SARS-CoV-2 from other respiratory infections to aid in guiding appropriate care
46 and management. Since the pandemic has affected millions of people, mass testing requires a
47 lot of resources. Further the WHO has suggested around 10 – 30 tests per Positive case as a

48 benchmark for adequate testing, it also has recommended a positive rate lower than 10% and
49 better if lower than 3%.²

50 In situations like this sample pooling can be a vital strategy to do testing in large numbers,
51 where sample extracts from a random number of samples from a heterogeneous population
52 group are combined into a single tube for pooled PCR analysis and this strategy have shown to
53 be cost-effective during mass testing compared with individual testing.³

54 When the disease prevalence is less, it can be advantageous to pool individual samples into a
55 single pool, this increases the test capacity and reduces the number of PCR tests.^{4,5} For
56 COVID-19, it has been estimated that pooling strategy reduces cost by 69% and use of tenfold
57 fewer tests.^{6,7} Recent research have also established the optimal pool size that maintains the
58 testing accuracy for SARS-CoV-2 PCR and has found that accuracy is retained in a pool size
59 of up to 32 samples. It has shown that costs can be reduced substantially without sacrificing
60 accuracy.⁸⁻¹⁰

61 However, when samples are diluted, there could be less viral genetic material available to
62 detect and this increases in greater likelihood of false negative results. But studies establish
63 that sample pooling will greatly increase the number of individuals that can be tested using less
64 resource with a small reduction in sensitivity, which may be acceptable depending on the
65 pooling efficiency¹¹ Therefore, the FDA generally recommends that pooling test shows $\geq 85\%$
66 percent positive agreement when compared with the same test performed on individual
67 samples.

68 In UAE, as of November 2020, there are around 1500 COVID -19 cases per 100K population
69 and UAE is in the top compared to other nations in the number of tests done per 100K
70 population.¹² Around 149,000 tests are done per 100K population and the positive rate is 1%.

71 [Figure 1]. With this background, the study aims to evaluate the pooling strategy for mass
72 screening of COVID-19.

73 **Aim**

74 The aim of the study is to evaluate the pooling method for mass screening of COVID-19.

75 **Objectives**

- 76 • To evaluate the sensitivity of 4 and 8 sample pooling for testing COVID -19.
- 77 • To study the repeatability and reproducibility of sample pooling by doing a inter and
78 intra assay precision analysis

79

80 **Materials and method**

81 The samples for this study were collected from individuals using nasopharyngeal swabs and
82 were transported to the viral transport medium (VTM). All methods were carried out in
83 accordance with relevant guidelines and regulations. Then RNA extraction was done by the
84 automated machine MGISP -960. After the RNA extraction, 10 microliters of the sample
85 extract is added to 20 microliter of the master mix (BGI RT-PCR fluorescence KIT). Every
86 plate has a positive control and a negative or blank control.

87 In individual sample extraction, 160 microliters of the sample were used in each well, for the
88 pooled sample 160 microlitre in each well was constituted by 40 microlitre of each sample in
89 4 fold pool sampling and 20 microlitre of each sample for 8 fold pool sampling.

90 Then the pooled samples are extracted following the RT- PCR procedure. VIC channel
91 represents the B-actin housekeeping gene as internal control while FAM channel represents the
92 ORF1ab gene for SARS-COV-2 virus detection. A positive test specimen is one for which VIC

93 must have a cycle threshold (Ct) value ≤ 32 and FAM Ct ≤ 35 , both fluorescence curves should
94 be S shaped. A negative sample is one where there is no fluorescence curve at the FAM channel
95 and a CT value of < 32 and S shaped curve at the VIC channel.

96 If “S” shaped fluorescence curve is detected with a FAM Ct > 35 , re-extraction is done and RT
97 PCR test is repeated, if a negative result is detected, it is reported negative and if “S” curve is
98 detected with a FAM Ct ≤ 38 in re extraction results, then a positive report is given.

99 **Sensitivity of pooled sample**

100 For the sensitivity analysis, 40 known positive samples and 280 known negative samples were
101 taken. In the 4-fold pool sample testing 40 known positive samples and 120 known negative
102 samples were tested and in 8-fold pool sample testing, 40 known positive samples and 280
103 known negative samples were tested. Each well contained one known positive and 3 known
104 negative samples in the 4pool method and each well contained one known positive and 7 known
105 negative samples in the 8-pool sampling.

106 To analyse the sensitivity of sample of various viral load, out of the 40 samples used for pooling
107 , ten high viral load samples [HP] with Ct ≤ 20 , ten medium viral load samples [MP] with Ct $>$
108 20 to < 30 and twenty low viral load or weak positives samples [WP] with Ct > 30 were used.

109 The sensitivity of the 4-pool sampling and 8 - pool sampling was determined by running the
110 samples individually and the same samples were run in 4 and 8 pooled sample method and the
111 ability to detect the true positives were compared.

112 **Precision**

113 To assess the precision of pooled sample method intra and inter assay precision study were
114 conducted.

115 **Intra assay precision**

116 Intra assay precision was calculated by running 30 known positive samples in 4 pool and 8
117 pool sampling twice. 30 known positive samples were classified into three groups of 10
118 samples each based on the CT values as high viral load samples [HP] medium viral load
119 samples [MP] and low viral load or weak positives samples [WP] as mentioned above.

120 All these samples were run twice, and the variability was assessed calculating the coefficient
121 of variation (CoV %).

122

123 **Inter assay precision**

124 Inter assay precision was calculated by running 30 known positive samples, which was again
125 classified into three groups based on the CT values as above. These samples were run on three
126 consecutive days and the variability was assessed calculating the coefficient of variation (CoV
127 %).

128 While doing the intra and inter assay experiment three known negative samples have been
129 added to the same well along with one of the 30 known positive samples for 4 pool sample and
130 seven known negative were added to the same pool along with one known positive for 8 pool
131 sample .

132 **Results**

133 Our study showed that the sensitivity of 4 pooled sample was 75% and the sensitivity of 8
134 pooled sample was 62.5% (Table 1 and table 2). The sensitivity decreases from 75% in 4 pool
135 sampling to 62.5% in 8 pool sampling. In the low viral load, weak positive samples (Ct value
136 ≥ 35), sensitivity of 4 pool sample was 50% (Table 3) and it further reduces to 25% in 8 pool
137 sampling with a false negative percentage as high as 75%. (Table 4)

138 The Ct difference was calculated between individual and pooled sample and the difference
139 increased with the increase in pool size, the difference was more pronounced in the low viral
140 load, weak positive group. (Table 5). The median Ct difference increased with increase in pool
141 size and the maximum values were observed in weak viral load positive pooled samples. In the
142 weak viral load positive sample pooling, the median became almost 0, as most samples turned
143 negative with Ct value of 0 in the 8 pool of weak viral load positive sample. [Fig 2, 3,4]

144 Table 6, shows the discrepancies in results of the 40 positive samples, there were totally 15
145 positive samples that missed detection after the samples were pooled.

146 The % CV (Coefficient of variance) ranged from 0 – 4% in intra and inter assay of 4 pool
147 samples of high and medium viral load positive samples, however inter assay of 8 pool sample
148 and weak positive samples of 4 pool and 8 pool both inter and intra assay were very high (Table
149 7 and Table 8)

150 **Discussion**

151 Our study showed that the strategy of pooling of samples for COVID-19 RT-PCR, has lower
152 sensitivity than the standard individual RT-PCR and the sensitivity decreases with the increase
153 in the pool size. Further when weak viral load positive samples were pooled the sensitivity
154 became as low as 25%, which leads to increased false negatives. Similar studies have reported
155 varied results, some studies have claimed pooling to be an effective strategy, a study done in
156 Malaysia showed that pools of 10 samples were similar in sensitivity compared to individual
157 testing.¹⁴ A study in UK, has strongly supported pooled approach and reports a clinically
158 insignificant sensitivity loss when samples are pooled and false positive rate up to 5.3%.¹⁵ But
159 another study done in Spain evaluating the sensitivity of pooled samples, testing various

160 solutions and VTM showed that the sensitivity varied from 62.5 % to 81% and false negatives
161 were as high as up to 40 % .¹⁶

162 The study also showed that the pooling resulted in a median loss of 2.29 Ct for high viral load
163 positive 4 -pool samples to median loss of – 36.01 Ct in 8 - pool low viral load positive
164 samples, this is because the samples became negative with Ct value 0, after 8 sample pooling.
165 This shows that in low viral load/ weak positive pooled samples the cycle threshold increased,
166 or most samples went undetected. A study in Kenya also showed that the cycle threshold values
167 were higher for samples which were pooled then tested individually.¹⁷ The study in Spain also
168 showed that sample dilution in pooling strategy resulted in a median loss of 2.8 to 3.3 Ct and
169 thereby drop in sensitivity.¹⁸

170 The coefficient of variation was high among the low viral load positive samples both in the
171 inter and intra assay, this shows the high variability in the results when the samples are pooled.
172 Higher Ct values in sample pooling method might be due to the inadequacy of samples when
173 they are pooled and lower Ct values in pool testing might be due to the carrier effect of the
174 higher RNA content in the pool. There is not much studies that have commented on %CV
175 variability pertaining to COVID-19 testing.¹⁹

176 When a person shows a weak positive result, that means that the viral load is low, so we need
177 to amplify it several more times to detect the virus, hence the high Ct value. This kind of weak
178 positives may be a of result of sample inadequacy or the person is in early/ late stage of
179 infection where the viral load is low. These samples are missed detection when they are pooled.
180 Such weak positive samples may pose a significant threat of spreading the infection to others.
181 Studies on the clinical significance of low viral load positive cases are needed, and it remains
182 a question of whether it is safe to miss detection of such cases?

183 Pooling samples can be very challenging logistically, usually in pool testing if a pooled sample
184 tests negative, then all samples within that pool are deemed negative and if a pool tests positive,
185 then individual samples making up that pool are tested again as individual samples to identify
186 the positives. Hence the larger the pool the more challenging is the deconvolution.²⁰ Further
187 there is additional time required in deconvoluting larger pools, which leads to time delay in
188 reporting and this becomes crucial in severely ill patients and the high-risk contacts where early
189 reporting is requisite.²¹ Not to neglect the anxiety caused by isolation in patients included in
190 the positive sample pools, until retesting of the individual samples is completed.

191 A lot of factors affect the sensitivity of RT-PCR, like the sensitivity of the kit, dilution used,
192 the techniques of sample collection, type of samples (NPS vs oropharyngeal vs nasal etc),
193 sample transport temperature, viral load in the sample which varies according to the stage of
194 infection.^{22,23} Therefore RT-PCR of sample pooling strategy has its own limitations, it cannot
195 ensure the diagnostic integrity of the individual sample,²⁴ it can mask the technical errors like
196 insufficient sampling,^{19,25} it has higher percentage of false negatives,¹⁰ reduces sensitivity²⁶
197 and sample dilution has led to the risk of missing weak viral load or borderline positive
198 samples^{17,21} Although pooling of samples facilitates rational use of resources, it might miss
199 individuals who might be positive for COVID-19.^{27,28}

200 This information becomes crucial for deciding the pooled strategy testing for disease like
201 COVID -19. In the current pandemic, we simply can't afford to miss any positive cases. With
202 the high R_0 value around 3 for SARS-COV-2,²⁹ every missed positive case can lead to rapid
203 spread of infection to others.

204 **Limitations**

205 Our study was conducted in a single laboratory in a defined geographical area, more studies
206 and data are needed to validate sample pooling strategies and the clinical significance and threat
207 of communicability of weak positive samples.

208 **Conclusion**

209 Based on the study results, we conclude that pooled testing strategy misses low viral load/ weak
210 positive COVID – 19 cases and there is high variability in results when the samples are pooled.
211 While in a low resource setting, where pooled sample testing is better than not having any kind
212 of testing, sample pooling might be an effective way for mass screening and the increase in
213 percentage of false negative tests may be dismissed, but caution is advised and it needs careful
214 scrutiny. In the current scenario of the pandemic, validation studies on the cost-effective
215 analysis of pooling samples should be done, considering the cost and risk of missing even a
216 single positive person. As COVID - 19 numbers are still high and testing capacity needs to be
217 high, we have to meticulously evaluate the testing strategy of each country depending on its
218 testing capacity, infrastructure, economic strength, and need to make a serious call on cost
219 effective strategy of resource saving and cost of missing positive patients.

220 **Declarations**

221 **Ethics approval and consent to participate**

222 The Ethics approval was obtained from Department of Health (DOH) Institutional review
223 board (IRB), Abu Dhabi

224 All methods were carried out in accordance with relevant guidelines and regulations. The
225 Department Of Health (DOH) Institutional review board (IRB), Abu Dhabi

226 has waived off the consent as it does not use any participant data/ information, the lab data on
227 the viral samples were only used for this study

228 Consent for publication – Not applicable

229 **Data Availability**

230 The data is available with the corresponding author, Dr. Sally, Director of Biogenix G42 lab
231 and will be produced on request

232 **Competing interests**

233 The authors declare that they have no competing interests regarding the publication of this
234 paper

235 **Funding statement**

236 The study was not funded by any funding body, it was done in Biogenix lab as a part of research

237 **Authors' contribution**

238 SM – conception, design of work, acquisition, analysis, interpretation of data, drafted and
239 substantively revised the manuscript

240 EI – conception, design of work, acquisition, analysis, interpretation of data, drafted and
241 substantively revised the manuscript

242 BT- conception, design of work, interpretation of data, drafted and substantively revised the
243 manuscript

244 JT- conception, design of work, interpretation of data, drafted and substantively revised the
245 manuscript

246 PR- conception, design of work, drafted and substantively revised the manuscript

247 SG-Acquisition, analysis, interpretation of data, drafted and substantively revised the

248 manuscript

249 WA- conception, drafted and substantively revised the manuscript

250 **Acknowledgments**

251 We acknowledge all lab personnel, skilled technicians who provided help during the research

252 and preparation of the manuscript

253 **References**

254 1. Mahase Elisabeth. Coronavirus: covid-19 has killed more people than SARS and

255 MERS combined, despite lower case fatality rate BMJ 2020; 358 :m461

256 2. WHO. COVID-19 - virtual press conference - 30 March 2020. Available at:

257 [https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2)

258 [emergencies-coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2)

259 3. Deckert, Barnighausen, NA Kyei. Simulation of pool sampling analysis strategy for

260 COVID – 19 mass testing. Bulletin of the World Health Organization 2020;98:590-598.

261 Available at: <https://www.who.int/bulletin/volumes/98/9/20-257188/en/>

262 4. Hogan CA, Sahoo MK, Pinsky BA. Sample pooling as a strategy to detect community

263 transmission of SARS-CoV-2. JAMA. 2020. <https://doi.org/10.1001/jama.2020.5445>.

264 5. Cherif A, Grobe N, Wang X, Kotanko P. Simulation of Pool Testing to Identify Patients

265 With Coronavirus Disease 2019 Under Conditions of Limited Test Availability. JAMA

266 Network Open. 2020;3(6):e2013075.

- 267 6. Abdalhamid B, Bilder CR, McCutchen EL, Hinrichs SH, Koepsell SA, Iwen PC.
268 Assessment of specimen pooling to conserve SARS CoV-2 testing resources. *Am J Clin*
269 *Pathol.* 2020;153(6):715–8.
- 270 7. Verdun CM, Fuchs T, Harar P, Elbrächter D, Fischer DS, Berner J, Grohs P, Theis FJ,
271 Krahmer F. Group testing for SARS-CoV-2 allows for up to 10-fold efficiency increase
272 across realistic scenarios and testing strategies. *medRxiv.* 2020
-
- 273 8. Ben-Ami R, Klochendler A, Seidel M, Sido T, Gurel-Gurevich O, Yassour M, et al.
274 Large-scale implementation of pooled RNA-extraction and RT-PCR for SARS-
275 CoV-2 detection [preprint]. Cold Spring Harbor: medRxiv; 2020. Available
276 from: <https://www.medrxiv.org/content/10.1101/2020.04.17.20069062v2> [cited
277 2020 Nov 12].
- 278 9. Schmidt M, Hoehl S, Berger A, Zeichhardt H, Hourfar K, Ciesek S, et al. FACT –
279 Frankfurt adjusted COVID-19 testing – a novel method enables high-throughput
280 SARS-CoV-2 screening without loss of sensitivity [preprint]. Cold Spring Harbor:
281 medRxiv; 2020. Available
282 from: <https://www.medrxiv.org/content/10.1101/2020.04.28.20074187v1> [cited
283 2020 Nov 12].
- 284 10. Yelin I, Aharony N, Shaer Tamar E, Argoetti A, Messer E, Berenbaum D, et al.
285 Evaluation of COVID-19 RT-qPCR test in multi-sample pools. *Clin Infect Dis.* 2020
286 May 2;ciaa531. <http://dx.doi.org/10.1093/cid/ciaa531> pmid: [32358960](https://pubmed.ncbi.nlm.nih.gov/32358960/)
- 287 11. FDA. USA. Pooled sample testing and screening testing for COVID-19. Available at:
288 [https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/pooled-sample-testing-and-screening-testing-covid-19)
289 [devices/pooled-sample-testing-and-screening-testing-covid-19](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/pooled-sample-testing-and-screening-testing-covid-19)

- 290 12. Federal Competitiveness and Statistics centre. FCSA. UAE Ministry of Cabinet Affairs.
291 Available at: <https://fcsa.gov.ae/en-us/Pages/Covid19/UAE-Covid-19-Updates.aspx>
- 292 13. Our World in Data. United Arab Emirates. Coronavirus pandemic country profile.
293 Available at: [https://ourworldindata.org/coronavirus/country/united-arab-](https://ourworldindata.org/coronavirus/country/united-arab-emirates?country=~ARE)
294 [emirates?country=~ARE](https://ourworldindata.org/coronavirus/country/united-arab-emirates?country=~ARE)
- 295 14. Lim KL, Johari NA, Wong ST, Khaw LT, Tan BK, Chan KK, Wong SF, Chan WL,
296 Ramzi NH, Lim PK, Hakim SL. A novel strategy for community screening of SARS-
297 CoV-2 (COVID-19): Sample pooling method. PloS one. 2020 Aug 28;15(8):e0238417.
- 298 15. Iacobucci G. Covid-19: Study findings strongly support use of pooled testing, say
299 researchers. BMJ 2020;371:m4267
- 300 16. Alcoba-Florez J, Gil-Campesino H, de Artola DG, González-Montelongo R,
301 Valenzuela-Fernández A, Ciuffreda L, Flores C. Sensitivity of different RT-qPCR
302 solutions for SARS-CoV-2 detection. International Journal of Infectious Diseases. 2020
303 Oct 1;99:190-2.
- 304 17. Agoti, Charles & Mutunga, Martin & Lambisia, Arnold & Kimani, Domtila &
305 Cheruiyot, Robinson & Kiyuka, et al. Pooled testing conserves SARS-CoV-2
306 laboratory resources and improves test turn-around time: experience on the Kenyan
307 Coast. Wellcome Open Research. 5. 186. 10.12688/wellcomeopenres.16113.1.
- 308 18. de Salazar A, Aguilera A, Trastoy R, et al. Sample pooling for SARS-CoV-2 RT-PCR
309 screening [published online ahead of print, 2020 Sep 10]. *Clin Microbiol Infect.*
310 2020;S1198-743X(20)30537-1.
- 311 19. Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geißler T, Gärtner B, Becker SL,
312 Schneitler S, Smola S. Pooling of samples for testing for SARS-CoV-2 in asymptomatic
313 people. The Lancet Infectious Diseases. 2020 Apr 28.

- 314 20. Ball J, McNally A. Pooled testing for SARS-CoV-2 could provide the solution to UK's
315 testing strategy. *bmj*. 2020 Nov 9;371:m4312
- 316 21. Mishra B, Behera B, Mohanty M, Ravindra A, Ranjan J. Challenges and issues of
317 SARS-CoV-2 pool testing. *Lancet Infect Dis*. 2020 Nov;20(11):1233. doi:
318 10.1016/S1473-3099(20)30463-1. Epub 2020 Jul 14. PMID: 32679083.
- 319 22. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P,
320 del Campo R, Ciapponi A, Sued O, Martinez-Garcia L, Rutjes A, Low N, Perez-
321 Molina JA. False-negative results of initial RT-PCR assays for COVID-19: a
322 systematic review. *medRxiv*. 2020 Jan 1.
- 323 23. Afzal A. Molecular diagnostic technologies for COVID-19: Limitations and
324 challenges. *J Adv Res*. 2020 Nov;26:149-159. doi: 10.1016/j.jare.2020.08.002. Epub
325 2020 Aug 6. PMID: 32837738; PMCID: PMC7406419.
- 326 24. CDC. Interim Guidance for Use of Pooling Procedures in SARS-CoV-2 Diagnostic,
327 Screening, and Surveillance Testing. Available at :
328 <https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html>
- 329 25. Mishra B, Behera B, Mohanty M, Ravindra A, Ranjan J. Challenges and issues of
330 SARS-CoV-2 pool testing. *The Lancet Infectious Diseases*. 2020 Nov 1;20(11):1233.
- 331 26. Pikovski A, Bentele K. Pooling of coronavirus tests under unknown prevalence.
332 *Epidemiology & Infection*. 2020;148.
- 333 27. Abdalhamid B, Bilder CR, Garrett JL, Iwen PC (2020) Cost Effectiveness of Sample
334 Pooling to Test for SARS-CoV-2. *J Infect Dev Ctries* 14:1136-1137. doi:
335 10.3855/jidc.13935
- 336 28. Centers for Disease Control and Prevention. *Evaluating and testing persons for*
337 *coronavirus disease 2019 (COVID-19). Updated March 24, 2020. Accessed March 25*
338 *2020.* <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html>

339 29. D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction
340 number, R_0 , based on the early phase of COVID-19 outbreak in Italy. Biosaf Health.
341 2020 Jun;2(2):57-59. doi: 10.1016/j.bsheal.2020.03.004. Epub 2020 Apr 2. PMID:
342 32835209; PMCID: PMC7148916.

343

344

345 **Table 1: Sensitivity of 4 sample pooling**

Pooling method	Standard method (Individual sample run)		
	Positive	Negative	Total
Positive	30	0	30
Negative	10	0	10
Total	40		40

346 Sensitivity– 75% (CI - 61.7% - 88.3%)

347 False negative percentage – 25%

348 **Table 2: Sensitivity of 8 sample pooling**

Pooling method	Standard method		
	Positive	Negative	Total
Positive	25	0	27
Negative	15	0	13
Total	40		40

349 Sensitivity – 62.5% (CI – 47.5% - 77.5%)

350 False negative percentage – 37.5%

351 **Table 3: Sensitivity of 4 sample pooling of 20 weak positive samples with Ct value more**
352 **than 35**

Pooling method	Standard method		
	Positive	Negative	Total
Positive	10	0	30
Negative	10	0	10
Total	20		40

353

354 Sensitivity– 50 % (CI – 28.09 % - 71.91%)

355 False negative percentage – 50%

356 **Table 4 : Sensitivity of 8 sample pooling of 20 weak positive samples with Ct value more**
357 **than 35**

Pooling method	Standard method		
	Positive	Negative	Total
Positive	5	0	5
Negative	15	0	15

Total	20		20
-------	----	--	----

358

359 Sensitivity – 25 % (CI – 6.03 % - 43.97%)

360 False negative percentage – 75%

361 **Table : 5 Median Ct difference between individual and pooled samples**

Pool details	Ct difference (Median)	Interquartile range (IQR)
4 pool (HP)	2.29	0.49
4 pool (MP)	1.79	0.79
4 pool (WP)	- 18.26	39.60
8 pool (HP)	3.10	1.38
8 pool (MP)	2.66	1.21
8 pool (WP)	-36.01	28.81

362

363 * HP – High viral load positive sample, MP- Medium viral load positive sample, WP- low
364 viral load/ weak positive sample

365 **Table 6: Test result discrepancies in pool sample testing**

Samples	Original	4 pool testing	8 pool testing
High viral load positive samples (HP)			
1	Positive	Positive	Positive
2	Positive	Positive	Positive
3	Positive	Positive	Positive

4	Positive	Positive	Positive
5	Positive	Positive	Positive
6	Positive	Positive	Positive
7	Positive	Positive	Positive
8	Positive	Positive	Positive
9	Positive	Positive	Positive
10	Positive	Positive	Positive
Medium viral load positive sample (MP)			
11	Positive	Positive	Positive
12	Positive	Positive	Positive
13	Positive	Positive	Positive
14	Positive	Positive	Positive
15	Positive	Positive	Positive
16	Positive	Positive	Positive
17	Positive	Positive	Positive
18	Positive	Positive	Positive
19	Positive	Positive	Positive
20	Positive	Positive	Positive
Low viral load// weak positive samples (WP)			
21	Positive	Negative	Negative
22	Positive	Positive	Positive
23	Positive	Positive	Positive
24	Positive	Positive	Positive
25	Positive	Negative	Negative

26	Positive	Negative	Negative
27	Positive	Negative	Negative
28	Positive	Positive	Negative
29	Positive	Negative	Negative
30	Positive	Positive	Negative
31	Positive	Negative	Negative
32	Positive	Negative	Negative
33	Positive	Positive	Positive
34	Positive	Negative	Negative
35	Positive	Positive	Positive
36	Positive	Negative	Negative
37	Positive	Positive	Negative
38	Positive	Positive	Negative
39	Positive	Positive	Negative
40	Positive	Negative	Negative

366

367 **Table 7: Intra and inter assay of 4 pooled sampling**

	Coefficient of Variation %
Intra assay	
High viral load positive samples	0 – 2 %
Medium viral load positive samples	0 - 2%
Low viral load/ Weak positives	2 - 141 %
Inter assay	


High viral load positive samples	1 – 2 %
Medium viral load positive samples	1- 4 %
Low viral load/ Weak positives	1- 173%

368

369 **Table 8 : Intra and inter assay of 8 pooled sampling**

	Coefficient of Variation %
Intra assay	
High viral load positive samples	0 - 4%
Medium viral load positive samples	0 – 3%
Low viral load/ Weak positives	2- 141%
Inter assay	
High viral load positive samples	2 – 14%
Medium viral load positive samples	2 – 87 %
Low viral load/ Weak positives	26-173%

370 **Fig 1: Shows the number of COVID – 19 tests done per 1000 people ¹³**




371

372

373 **Figure 2: The Ct values of High viral load positive (HP) samples**

374




375

376

377

378 **Figure 3 : The Ct values of Medium viral load positive(MP) samples**


379



380

381

382 **Figure 4: The Ct values of low viral load / weak positive (WP) samples**



383

384

385